β-Cell replacement as a treatment for type 1 diabetes: an overview of possible cell sources and current axes of research.
To efficiently treat type 1 diabetes, exogenous insulin injections currently represent the main approach to counter chronic hyperglycaemia. Unfortunately, such a therapeutic approach does not allow for perfectly maintained glucose homeostasis and, in time, cardiovascular complications may arise. Therefore, seeking alternative/improved treatments has become a major health concern as an increasing proportion of type 2 diabetes patients also require insulin supplementation. Towards this goal, numerous laboratories have focused their research on β-cell replacement therapies. Herein, we will review the current state of this research area and describe the cell sources that could potentially be used to replenish the depleted β-cell mass in diabetic patients.
Université Côte d'Azur, CNRS, Inserm, iBV, France.
A
A
Vieira
Université Côte d'Azur, CNRS, Inserm, iBV, France.
M
M
Courtney
Université Côte d'Azur, CNRS, Inserm, iBV, France.
N
N
Druelle
Université Côte d'Azur, CNRS, Inserm, iBV, France.
F
F
Avolio
Université Côte d'Azur, CNRS, Inserm, iBV, France.
T
T
Napolitano
Université Côte d'Azur, CNRS, Inserm, iBV, France.
B
B
Hadzic
Université Côte d'Azur, CNRS, Inserm, iBV, France.
S
S
Navarro-Sanz
Université Côte d'Azur, CNRS, Inserm, iBV, France.
N
N
Ben-Othman
Université Côte d'Azur, CNRS, Inserm, iBV, France. collombat@unice.fr.
P
P
Collombat
D002454:Cell Differentiation; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D000067470:Cellular Reprogramming Techniques; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D022781:Hepatocytes; D000066449:Human Embryonic Stem Cells; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D057026:Induced Pluripotent Stem Cells; D007328:Insulin / Q000627:therapeutic use; D050417:Insulin-Secreting Cells / Q000637:transplantation*; D016381:Islets of Langerhans Transplantation / Q000379:methods; D010179:Pancreas / Q000166:cytology; D013234:Stem Cells
D007004:Hypoglycemic Agents; D007328:Insulin
stem cells; transdifferentiation; transplantation; type 1 diabetes; β-cells